CTLA4 antibody

A CTLA4 antibody (anti-CTLA-4 antibody) is a type of immune checkpoint inhibitor designed to target and block Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). CTLA-4 is a receptor expressed on T cells that acts as an immune system "off" switch by outcompeting the co-stimulatory receptor CD28 for binding to CD80 and CD86 on antigen-presenting cells. By binding to CTLA-4, these antibodies prevent this inhibitory interaction, allowing T cells to remain active, proliferate, and mount an effective immune response against cancer cells. Clinically approved CTLA-4 antibodies, such as ipilimumab and tremelimumab, are utilized either as monotherapies or in combination with other immunotherapies (like anti-PD-1/PD-L1 antibodies) to treat various malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma.

Other names

CTLA-4 antibodyCTLA4 antibodyCTLA 4 antibodyanti-CTLA-4 antibodyanti-CTLA4 antibodyanti-CTLA 4 antibodycytotoxic T-lymphocyte-associated protein 4 antibody